摘要
目的探讨雄激素受体剪接变异体7(AR-V7)在前列腺癌组织中的表达及临床意义。方法收集2017年3月至2019年3月大连医科大学附属大连市中心医院泌尿外科48例患者的组织标本。其中良性前列腺增生18例(良性增生组)、局限性前列腺癌18例(局限癌组)、前列腺癌骨转移12例(骨转移癌组)。免疫组化染色检测各组AR-V7阳性表达;qRT-PCR检测各组AR-V7 mRNA的表达。结果免疫组化结果显示3组比较AR-V7阳性表达存在统计学差异(P<0.05)。qRT-PCR检测结果显示,与良性增生组比较,局限癌组AR-V7 mRNA表达增高(P<0.05);与良性增生组和局限癌组比较,骨转移癌组AR-V7 mRNA表达增高(P<0.05)。结论前列腺癌组织中AR-V7表达增高,且与前列腺癌的临床进展相关,提示AR-V7可能参与前列腺癌的临床进展和骨转移的发生。
Objective To investigate expression of androgen receptor splicing variant 7(AR-V7)in prostate cancer tissues,and its clinical significance.Methods Tissue specimens were collected from 48 patients from March 2017 to March 2019 in the Department of Urology,Dalian Municipal Central Hospital of Dalian Medical University.Specimens represented 18 cases of benign prostatic hyperplasia(benign hyperplasia group),18 cases of localized prostate cancer(localized cancer group)and 12 cases of prostate cancer metastases to bone(bone metastatic cancer group).Immunohistochemical staining detected AR-V7 expression in each group.qRT-PCR detected AR-V7 mRNA expression in each group.Results Immunohistochemistry revealed a statistically significant difference in AR-V7 expression among the three groups(P<0.05).qRT-PCR showed that AR-V7 mRNA expression was elevated in the localized cancer group compared with the benign hyperplasia group(P<0.05),and was further elevated in the bone metastatic cancer group compared with the benign hy-perplasia and localized cancer groups(P<0.05).Conclusion AR-V7 expression was elevated in prostate cancer tissues in correlation with the clinical progression of prostate cancer,suggesting that AR-V7 may be involved in clinical progression of prostate cancer and oc-currence of bone metastasis.
作者
王艳龙
张洪麟
杜浩
任宇
于广海
刘志宇
WANG Yanlong;ZHANG Honglin;DU Hao;REN Yu;YU Guanghai;LIU Zhiyu(Department of Urology,Dalian Municipal Central Hospital of Dalian Medical University,Dalian 116033,China;Center for Reproductive Health,Dalian Maternity Hospital of Dalian Medical University,Dalian 116033,China;Department of Urology,The Second Hospital of Dalian Medical Uni�versity,Dalian 116023,China)
出处
《中国医科大学学报》
CAS
CSCD
北大核心
2021年第8期678-680,689,共4页
Journal of China Medical University
基金
国家自然科学基金(81772739)
大连市医学科学研究计划项目(1711020)。
关键词
雄激素受体剪接变异体7
前列腺癌
临床意义
androgen receptor splicing variant 7
prostate cancer
clinical significance